I am not surprised if more stringent requirements are applied to more advanced clinical trials. Brakes could be applied whenever new findings are released or new concerns are addressed. Retail investors are always poorly informed like outsiders.
- Forums
- ASX - By Stock
- ATH
- SRPT Duchenne Drug trial hits 5 year mark
SRPT Duchenne Drug trial hits 5 year mark, page-50
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
|
|||||
Last
0.4¢ |
Change
-0.001(12.5%) |
Mkt cap ! $21.28M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $7.902K | 2.037M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
41 | 53613756 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 127138639 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
41 | 53613756 | 0.003 |
63 | 91698098 | 0.002 |
29 | 124621099 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 127138639 | 21 |
0.005 | 32607632 | 31 |
0.006 | 15128927 | 24 |
0.007 | 55054408 | 29 |
0.008 | 18128275 | 22 |
Last trade - 14.03pm 15/08/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online